Trial reportThe New England journal of medicine2023
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
Trial report in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients
Incidence and Burden of Bleeding in Multiple Myeloma Patients Receiving Thromboprophylaxis
Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Aspirin vs. enoxaparin for thromboprophylaxis after total hip arthroplasty, total knee arthroplasty, or hip fracture surgery-a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis.Scientific reports · 2025Pooled it
- Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2024Pooled it
- Low molecular weight heparin dosing regimens after total joint arthroplasty: a prospective, single-center, randomized, double-blind study.Journal of orthopaedic surgery and research · 2024Trial
- Trial
- Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial.JAMA network open · 2023Trial
- Incidence and factors influencing the occurrence of postoperative thrombosis in patients with lower limb fractures across different age groups: a retrospective study.Annals of medicine · 2026Article
- Aspirin vs. Low-Molecular-Weight Heparin in Orthopedic Trauma: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Extended venous thromboembolism prophylaxis after bariatric surgery: the potential role of aspirin.Annals of medicine and surgery (2012) · 2026Article
- Superficial femoral artery thrombosis after PFNA in an intertrochanteric fracture patient with sarcopenia and copd: a rare case report.BMC geriatrics · 2026Article
- Aspirin for Venous Thromboembolism Prevention in Orthopaedic Surgery with Focus on Trauma and Arthroplasty: A Structured Evidence-Based Review of Randomised Trials, Guidelines, and Contemporary Practice Considerations.Journal of clinical medicine · 2026Review
- Article
- Timing and Trends of Periprosthetic Joint Infections Following Over 1,500,000 Primary and Revision Total Knee and Hip Arthroplasty Cases.Arthroplasty today · 2026Article
- Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures.Acta orthopaedica et traumatologica turcica · 2026Article
- Bridging practice and evidence: insights from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine and Saudi Critical Care Society Guidelines on trauma-related VTE.Scandinavian journal of trauma, resuscitation and emergency medicine · 2026Review
- Postoperative venous thromboembolism following cesarean delivery: prevalence, pathophysiology, diagnosis, treatment, and prevention.American journal of obstetrics and gynecology · 2026Review
- Rebound pain following peripheral nerve block in extremity fracture surgery: pathophysiological mechanisms based on the "Triple-Hit" model and multimodal preventive strategies.Frontiers in medicine · 2026Review
- Validation of the Caprini risk assessment model and efficacy of perioperative nutritional support + preventive nursing in reducing DVT among high-risk older adults undergoing hip fracture surgery: a two-phase study.Frontiers in medicine · 2026Article
- Meta-analysis of Randomized Trials in Emergency and Acute Orthopedic Trauma Comparing Aspirin and Low-Molecular-Weight Heparin for Thromboprophylaxis.Orthopedic reviews · 2026Article
- Graduated Compression Stockings for Thromboprophylaxis in Orthopaedic and Trauma Surgery: A Rapid Review and Meta-Analysis.Journal of clinical medicine · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
backgroundClinical guidelines recommend low-molecular-weight heparin for thromboprophylaxis in patients with fractures, but trials of its effectiveness as compared with aspirin are lacking.
methodsIn this pragmatic, multicenter, randomized, noninferiority trial, we enrolled patients 18 years of age or older who had a fracture of an extremity (anywhere from hip to midfoot or shoulder to wrist) that had been treated operatively or who had any pelvic or acetabular fracture. Patients were randomly assigned to receive low-molecular-weight heparin (enoxaparin) at a dose of 30 mg twice daily or aspirin at a dose of 81 mg twice daily while they were in the hospital. After hospital discharge, the patients continued to receive thromboprophylaxis according to the clinical protocols of each hospital. The primary outcome was death from any cause at 90 days. Secondary outcomes were nonfatal pulmonary embolism, deep-vein thrombosis, and bleeding complications.
resultsA total of 12,211 patients were randomly assigned to receive aspirin (6101 patients) or low-molecular-weight heparin (6110 patients). Patients had a mean (±SD) age of 44.6±17.8 years, 0.7% had a history of venous thromboembolism, and 2.5% had a history of cancer. Patients received a mean of 8.8±10.6 in-hospital thromboprophylaxis doses and were prescribed a median 21-day supply of thromboprophylaxis at discharge. Death occurred in 47 patients (0.78%) in the aspirin group and in 45 patients (0.73%) in the low-molecular-weight-heparin group (difference, 0.05 percentage points; 96.2% confidence interval, -0.27 to 0.38; P<0.001 for a noninferiority margin of 0.75 percentage points). Deep-vein thrombosis occurred in 2.51% of patients in the aspirin group and 1.71% in the low-molecular-weight-heparin group (difference, 0.80 percentage points; 95% CI, 0.28 to 1.31). The incidence of pulmonary embolism (1.49% in each group), bleeding complications, and other serious adverse events were similar in the two groups.
conclusionsIn patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality. (Funded by the Patient-Centered Outcomes Research Institute; PREVENT CLOT ClinicalTrials.gov number, NCT02984384.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.